To evaluate the correlation between the changes in serum concentrations of cluster of differentiation-147 (scCD147) and chemotherapy outcome in patients with NSCLC and evaluate the combination of scCD147 with serum matrix metalloproteinase-9 (scMMP-9) levels in the prediction of chemotherapy response, eighty-two patients with advanced LC were enrolled. Newly diagnosed cases were treated with platinum-based chemotherapy. We measured scCD147 protein levels in LC cases by ELISA and used receiver operating characteristic (ROC) curves to analyze the results. Four time points were chosen to examine the association between the changes in scCD147 and chemotherapy outcome: before chemotherapy and 21 days after the start of the first, second, and fourth chemotherapy cycles. We assessed the combination of scCD147 and scMMP-9 serum levels in predicting the chemotherapy response. scCD147 was higher in LC cases than that in healthy volunteers (HVs). scCD147 was associated with distant metastases and TNM stage. scCD147 and scMMP-9 appeared to be independent predictive factors for chemotherapy outcomes after the first and second chemotherapy cycles for patients with NSCLC. Multivariable analysis also demonstrated that variations in scCD147 and scMMP-9 could be independent factors for monitoring chemotherapy outcome for patients with NSCLC. Furthermore, when scCD147 and scMMP-9 are combined into a new risk model, it has a markedly better prediction of chemotherapy outcomes than each protein alone. scCD147 and MMP-9 are potential predictive biomarkers for efficacy, and their combination significantly improves the predictive power for chemotherapy response in patients with NSCLC.

中文翻译：

---

CD147和MMP-9血清水平的组合被确定为晚期非小细胞肺癌的新型化疗反应标志物。

评估NSCLC患者血清分化簇147（scCD147）的浓度变化与化疗结果之间的相关性，并评估scCD147与血清基质金属蛋白酶9（scMMP-9）水平的组合以预测化疗反应，招募了82名晚期LC患者。新诊断的病例采用铂类化学疗法治疗。我们通过ELISA测量了LC病例中scCD147蛋白的水平，并使用了接收者操作特征（ROC）曲线来分析结果。选择四个时间点来检查scCD147的变化与化疗结果之间的关联：在化疗之前以及在第一个，第二个和第四个化疗周期开始后的21天。我们评估了scCD147和scMMP-9血清水平的组合，以预测化疗反应。LC患者中的scCD147高于健康志愿者（HV）。scCD147与远处转移和TNM分期有关。scCD147和scMMP-9似乎是NSCLC患者在第一个和第二个化疗周期后化疗结果的独立预测因素。多变量分析还表明，scCD147和scMMP-9的变异可能是监测NSCLC患者化疗结果的独立因素。此外，将scCD147和scMMP-9组合成新的风险模型后，与单独使用每种蛋白质相比，它对化疗结果的预测效果明显更好。scCD147和MMP-9是疗效的潜在预测生物标志物，